Surface Oncology, Inc. Banner Image

Surface Oncology, Inc.

  • Ticker SURF
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Surface Oncology, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (viaMore targeting CD112R, also known as PVRIG (SRF813)) or depleting regulatory T cells (via targeting CCR8 (SRF114)). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
Surface Oncology, Inc.

Most Recent Annual Report

Surface Oncology, Inc.
MOST RECENT 2020 Annual Report

Older/Archived Annual Reports